-
公开(公告)号：US12005117B2
公开(公告)日：2024-06-11
申请号：US16917157
申请日：2020-06-30
IPC分类号： A61P13/12 , A61K39/395 , C07K16/40 , A61K39/00
CPC分类号： A61K39/3955 , A61K39/395 , A61P13/12 , C07K16/40 , A61K2039/505 , A61K2121/00 , C07K2317/21 , C07K2317/34 , C07K2317/54 , C07K2317/76 , C07K2317/92
摘要： In one aspect, the invention provides methods for treating, inhibiting, alleviating or preventing fibrosis in a mammalian subject suffering, or at risk of developing a disease or disorder caused or exacerbated by fibrosis and/or inflammation. In one embodiment, the invention provides methods of treating a subject suffering from renal fibrosis. In one embodiment, the invention provides methods of reducing proteinuria in a subject suffering from a renal disease or condition associated with proteinuria. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation.
-
公开(公告)号：US11981749B2
公开(公告)日：2024-05-14
申请号：US16984509
申请日：2020-08-04
CPC分类号： C07K16/40 , A61P7/02 , A61P37/02 , C12Y304/21104 , A61K2039/505 , C07K2317/20 , C07K2317/21 , C07K2317/33 , C07K2317/55 , C07K2317/565 , C07K2317/622 , C07K2317/76 , C07K2317/92
摘要： In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a human subject suffering from TMA associated with hematopoietic stem cell transplant. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation.
-
3.发明公开公开(公告)号：US20240343830A1
公开(公告)日：2024-10-17
申请号：US18628104
申请日：2024-04-05
CPC分类号： C07K16/40 , A61P7/02 , A61P37/02 , C12Y304/21104 , A61K2039/505 , C07K2317/20 , C07K2317/21 , C07K2317/33 , C07K2317/55 , C07K2317/565 , C07K2317/622 , C07K2317/76 , C07K2317/92
摘要： In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a human subject suffering from TMA associated with hematopoietic stem cell transplant. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation.
-
4.发明申请公开(公告)号：US20210079116A1
公开(公告)日：2021-03-18
申请号：US16911682
申请日：2020-06-25
摘要： In one aspect, the invention provides methods for reducing proteinuria in a human subject suffering, or at risk of developing Immunoglobulin A Nephropathy (IgAN). The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory antibody effective to inhibit MASP-2-dependent complement activation.
-
公开(公告)号：US20210077621A1
公开(公告)日：2021-03-18
申请号：US16917157
申请日：2020-06-30
IPC分类号： A61K39/395 , A61P13/12 , C07K16/40
摘要： In one aspect, the invention provides methods for treating, inhibiting, alleviating or preventing fibrosis in a mammalian subject suffering, or at risk of developing a disease or disorder caused or exacerbated by fibrosis and/or inflammation. In one embodiment, the invention provides methods of treating a subject suffering from renal fibrosis. In one embodiment, the invention provides methods of reducing proteinuria in a subject suffering from a renal disease or condition associated with proteinuria. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation.
-
公开(公告)号：US20210047433A1
公开(公告)日：2021-02-18
申请号：US16984509
申请日：2020-08-04
摘要： In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a human subject suffering from TMA associated with hematopoietic stem cell transplant. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation.
-
7.发明公开公开(公告)号：US20240342278A1
公开(公告)日：2024-10-17
申请号：US18523203
申请日：2023-11-29
申请人： Omeros Corporation
发明人： W. Jason Cummings , Gregory A. Demopulos , Thomas A. Dudler , Larry W. Tjoelker , Christi L. Wood , Munehisa Yabuki
IPC分类号： A61K39/395 , B82Y25/00 , C01F17/206 , C07K16/40 , C09K11/77 , C12N9/64 , H01F1/00 , A61K39/00
CPC分类号： A61K39/3955 , B82Y25/00 , C01F17/206 , C07K16/40 , C09K11/77 , C09K11/7728 , C12N9/6424 , C12Y304/21104 , H01F1/0054 , A61K39/00 , A61K2039/505 , A61K2039/54 , A61K2039/545 , C01P2002/54 , C01P2002/84 , C01P2004/64 , C07K2317/24 , C07K2317/33 , C07K2317/34 , C07K2317/56 , C07K2317/565 , C07K2317/734 , C07K2317/76 , C07K2317/90 , C07K2317/92
摘要： The present invention relates to MASP-3 inhibitory antibodies and compositions comprising such antibodies for use in inhibiting the adverse effects of MASP-3 dependent complement activation.
-
公开(公告)号：US20220064330A1
公开(公告)日：2022-03-03
申请号：US17103672
申请日：2020-11-24
申请人： Omeros Corporation
摘要： In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a human subject suffering from, or at risk for developing HSCT-IPS and/or suffering from, or at risk for developing HSCT-CLS and/or suffering from, or at risk for developing HSCT-FO and/or suffering from, or at risk for developing HSCT-ES. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation.
-
公开(公告)号：US20240218080A1
公开(公告)日：2024-07-04
申请号：US18411789
申请日：2024-01-12
申请人： Omeros Corporation
CPC分类号： C07K16/40 , A61P27/10 , A61K2039/505 , A61K2039/545 , C07K2317/565 , C07K2317/76
摘要： In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a human subject suffering from, or at risk for developing HSCT-IPS and/or suffering from, or at risk for developing HSCT-CLS and/or suffering from, or at risk for developing HSCT-FO and/or suffering from, or at risk for developing HSCT-ES. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation.
-
10.发明公开公开(公告)号：US20230416406A1
公开(公告)日：2023-12-28
申请号：US18181437
申请日：2023-03-09
CPC分类号： C07K16/40 , A61P7/00 , C07K2317/24 , C07K2317/565
摘要： The present disclosure relates to the use of MASP-2 inhibitors and/or MASP-3 inhibitors and compositions comprising the same for treatment of sickle cell disease, including treatment, reduction, and/or prevention of sickle cell disease symptoms or manifestations.
-
-
-
-
-
-
-
-
-
搜索结果
10 条记录 (耗时 0.032 秒)
